At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 174 enrolled
Drug / intervention
zilucoplan (RA101495) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
In Brief
A Phase 3 clinical trial evaluating zilucoplan (RA101495) and Placebo for Myasthenia Gravis, Generalized. Completed, enrolled 174 participants across 77 sites in 10 countries.
Detailed Summary
The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyasthenia Gravis, Generalized
CountriesCanada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartSep 2019
First PostedOct 2019
Primary CompletionDec 2021
TodayJul 2026
First PostedOct 4, 2019
Enrollment StartSep 17, 2019
Primary CompletionDec 30, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.7 years ago
Interventions
zilucoplan (RA101495)drug
Daily subcutaneous (SC) injection
Placebodrug
Daily subcutaneous (SC) injection